The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

The FDA has granted expanded access authorisation for ImmunityBio’s Cancer BioShield platform, anchored by Anktiva, to treat ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease ...

Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.

CirCode Biomed’s circular RNA drug HM2002 has received IND clearance from the FDA for the treatment of ischaemic heart ...

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract ...

The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance ...

The HSS has terminated a contract previously awarded to Moderna to help advance a vaccine candidate targeting bird flu.